Peskind_1995_Biol.Psychiat_38_532

Reference

Title : Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma - Peskind_1995_Biol.Psychiat_38_532
Author(s) : Peskind ER , Wingerson D , Pascualy M , Thal L , Veith RC , Dorsa DM , Bodenheimer S , Raskind MA
Ref : Biological Psychiatry , 38 :532 , 1995
Abstract :

Physostigmine is a cholinesterase inhibitor which enhances central and peripheral cholinergic activity. In this study, we explored in persons with Alzheimer's disease (AD) the effects of an acute dose of physostigmine in patients receiving chronic physostigmine treatment on the activity of the cholinergically regulated noradrenergic and arginine vasopressin (AVP) systems. Specifically, we estimated the effects of sustained release oral physostigmine on central and peripheral noradrenergic and AVP systems by measuring norepinephrine (NE) and AVP in cerebrospinal fluid (CSF) and plasma. Lumbar punctures were performed in both physostigmine and no drug treatment conditions. In some subjects the effects of physostigmine on the plasma AVP response to the osmolar stimulus of a hypertonic saline infusion also were measured. NE concentrations in both CSF and plasma were significantly lower in the physostigmine than in the no drug condition. AVP concentrations did not differ between conditions in either compartment, nor did physostigmine affect the AVP response to hypertonic saline. Physostigmine appears to decrease both central and peripheral noradrenergic activity in AD.

PubMedSearch : Peskind_1995_Biol.Psychiat_38_532
PubMedID: 8562665

Related information

Citations formats

Peskind ER, Wingerson D, Pascualy M, Thal L, Veith RC, Dorsa DM, Bodenheimer S, Raskind MA (1995)
Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma
Biological Psychiatry 38 :532

Peskind ER, Wingerson D, Pascualy M, Thal L, Veith RC, Dorsa DM, Bodenheimer S, Raskind MA (1995)
Biological Psychiatry 38 :532